Anti-Cspg4 Fusions with Type I Interferon for the Treatment of Malignancy
技術優勢
The fused anti-CSPG4/interferon has shown high efficacy in inhibiting the growth of melanoma cell lines in cell culture and in immunodeficient mice.
技術應用
This technology can be used for treatment of a range of human cancers, including:MelanomaMultiple myelomaGliomaTriple-negative breast cancerChronic lymphocytic leukemia
詳細技術說明
UCLA researchers have developed antibody-IFN fusion proteins to selectively localize IFN at tumor sites. The fusion proteins were shown to inhibit the growth of melanoma cell lines in vitro and in vivo.
其他
State Of Development
Significant pre-clinical data has been obtained.
Background
Interferons (IFNs) are proteins made by the host cell in response to pathogens that are potent regulators of cell growth. In addition, IFNs possess inhibitory effects against many human cancers. However, since less than 0.01% of injected IFNα reaches the desired target tumor sites, the therapeutic cannot achieve effective concentrations at the tumor sites without also introducing significant systemic toxicity. Therefore, there exists an unmet need to develop antibodies to carry IFNs directly to cancer sites.
